Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Kidney (Renal Cell)
Kidney (Renal Cell)
This is a Phase 1b / 2 study of AVB-S6-500 designed to evaluate the safety and efficacy of AVB-S6-500 in combination with cabozantinib in subjects with advanced clear cell renal cell carcinoma (ccRCC) that have received front-line treatment. The phase 1b portion of the study is open label and patients will receive AVB-S6-500+Cabozantinib in 3+3 dose escalation. The Phase 2 portion of the study is randomized, 2-arm, open-label study to compare efficacy and tolerability of AVB-S6-500+cabozantinib versus cabozantinib alone
Kidney (Renal Cell)
I/II
Beckermann, Kathryn
NCT04300140
VICCUROP2016
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Multiple Cancer Types
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
Bladder,
Kidney (Renal Cell),
Rectal
II
Davis, Nancy
NCT03866382
ALLIANCEUROA031702
A multicenter Phase II trial of Paclitaxel with and without Nivolumab in Taxane naïve, and Nivolumab and Cabozantinib in Taxane pretreated subjects with angiosarcoma.
Sarcoma
Sarcoma
Sarcoma
II
Davis, Elizabeth
ALLIANCESARA091902